The global coronary artery bypass graft market size was estimated to be USD 12.99 billion in 2023 and is expected to reach USD 35.14 billion by 2034 with a CAGR of 9.47% during the forecast period 2024-2034. The market's growth will be fueled by rising rates of coronary artery disease (CAD), an aging population, greater technological advancements, and favorable reimbursement policies.
New surgical techniques, such as minimally invasive CABG, are less traumatic and require shorter recovery times, boosting patient preference for CABG treatments. Furthermore, innovations in graft materials and surgical instruments are increasing the success and safety of CABG procedures. For instance, the Valiant NavionTM Thoracic Stent Graft System, developed by Medtronic specifically for minimally invasive thoracic endovascular aortic repair (TEVAR) surgeries, was introduced in 2023. This technology offers more accurate deployment and better results for patients.
By procedure method, the off-pump segment accounted for the highest revenue-grossing segment in the global coronary artery bypass graft market in 2023 owing to the growing preference among surgeons and patients for off-pump CABG procedures, driven by the perceived benefits such as the reduced risk of complications, shorter recovery times, and potential cost savings associated with avoiding the use of cardiopulmonary bypass. Additionally, advancements in off-pump surgical techniques and technologies have further fueled the adoption of this segment, contributing to its dominance in the market. For instance, the FDA approved Boston Scientific's EluviaTM Drug-Eluting Vascular Stent System in 2023 so that it may be used in CABG surgeries. Sustained medication release is provided by this stent device, which improves vessel repair. Additionally, the minimally invasive direct segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for less invasive cardiac procedures, patient preference for reduced surgical trauma and quicker recovery times, advancements in technology facilitating precise and efficient minimally invasive direct CABG techniques, and the ongoing efforts of healthcare providers to enhance postoperative outcomes and overall patient satisfaction.
By surgical procedure, the single CABG surgery segment accounted for the highest revenue-grossing segment in the global coronary artery bypass graft market in 2023 owing to the prevalence of single-vessel coronary artery disease cases, the efficiency and effectiveness of single CABG surgery in addressing specific localized blockages, and the increasing adoption of this approach due to its reduced complexity and shorter procedural times compared to multi-vessel CABG. For instance, Medtronic finalized the acquisition of Affera, Inc. in August 2022. It is anticipated that this acquisition will broaden the company's offering of cardiovascular products. Additionally, the double CABG surgery segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing recognition of the clinical efficacy and benefits associated with addressing multiple coronary artery lesions in a single procedure, the rising incidence of multi-vessel coronary artery disease cases, and advancements in surgical techniques and technologies enabling safer and more efficient double CABG surgeries.
By end-user, the hospital segment accounted for the highest revenue-grossing segment in the global coronary artery bypass graft market in 2023 owing to the substantial volume of coronary artery bypass graft (CABG) procedures conducted within hospital settings, the availability of advanced medical infrastructure, specialized cardiac care units, and the expertise of trained healthcare professionals in managing complex cardiac surgeries. For instance, in 2023, Edwards Lifesciences announced a new collaboration with Google Cloud to create AI-driven heart disease management products. Additionally, the cardiology centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased focus on specialized cardiac care, advancements in diagnostic and treatment technologies within cardiology centers, and a growing trend towards outpatient cardiac procedures.
North American region is anticipated to have the highest revenue share during the forecast period owing to the robust healthcare infrastructure, high prevalence of coronary artery disease (CAD), widespread adoption of advanced medical technologies, and a well-established healthcare reimbursement system. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of coronary artery disease (CAD), rising healthcare investments, a growing aging population, and improving access to advanced healthcare facilities. For instance, Kimal PLC and Marizyme, Inc. announced a strategic partnership in February 2023 to support DuraGraft, the company's flagship product to prevent ischemia-reperfusion injury, a major contributing cause to vein graft disease.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
New surgical techniques, such as minimally invasive CABG, are less traumatic and require shorter recovery times, boosting patient preference for CABG treatments. Furthermore, innovations in graft materials and surgical instruments are increasing the success and safety of CABG procedures. For instance, the Valiant NavionTM Thoracic Stent Graft System, developed by Medtronic specifically for minimally invasive thoracic endovascular aortic repair (TEVAR) surgeries, was introduced in 2023. This technology offers more accurate deployment and better results for patients.
By procedure method, the off-pump segment accounted for the highest revenue-grossing segment in the global coronary artery bypass graft market in 2023 owing to the growing preference among surgeons and patients for off-pump CABG procedures, driven by the perceived benefits such as the reduced risk of complications, shorter recovery times, and potential cost savings associated with avoiding the use of cardiopulmonary bypass. Additionally, advancements in off-pump surgical techniques and technologies have further fueled the adoption of this segment, contributing to its dominance in the market. For instance, the FDA approved Boston Scientific's EluviaTM Drug-Eluting Vascular Stent System in 2023 so that it may be used in CABG surgeries. Sustained medication release is provided by this stent device, which improves vessel repair. Additionally, the minimally invasive direct segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for less invasive cardiac procedures, patient preference for reduced surgical trauma and quicker recovery times, advancements in technology facilitating precise and efficient minimally invasive direct CABG techniques, and the ongoing efforts of healthcare providers to enhance postoperative outcomes and overall patient satisfaction.
By surgical procedure, the single CABG surgery segment accounted for the highest revenue-grossing segment in the global coronary artery bypass graft market in 2023 owing to the prevalence of single-vessel coronary artery disease cases, the efficiency and effectiveness of single CABG surgery in addressing specific localized blockages, and the increasing adoption of this approach due to its reduced complexity and shorter procedural times compared to multi-vessel CABG. For instance, Medtronic finalized the acquisition of Affera, Inc. in August 2022. It is anticipated that this acquisition will broaden the company's offering of cardiovascular products. Additionally, the double CABG surgery segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing recognition of the clinical efficacy and benefits associated with addressing multiple coronary artery lesions in a single procedure, the rising incidence of multi-vessel coronary artery disease cases, and advancements in surgical techniques and technologies enabling safer and more efficient double CABG surgeries.
By end-user, the hospital segment accounted for the highest revenue-grossing segment in the global coronary artery bypass graft market in 2023 owing to the substantial volume of coronary artery bypass graft (CABG) procedures conducted within hospital settings, the availability of advanced medical infrastructure, specialized cardiac care units, and the expertise of trained healthcare professionals in managing complex cardiac surgeries. For instance, in 2023, Edwards Lifesciences announced a new collaboration with Google Cloud to create AI-driven heart disease management products. Additionally, the cardiology centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased focus on specialized cardiac care, advancements in diagnostic and treatment technologies within cardiology centers, and a growing trend towards outpatient cardiac procedures.
North American region is anticipated to have the highest revenue share during the forecast period owing to the robust healthcare infrastructure, high prevalence of coronary artery disease (CAD), widespread adoption of advanced medical technologies, and a well-established healthcare reimbursement system. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of coronary artery disease (CAD), rising healthcare investments, a growing aging population, and improving access to advanced healthcare facilities. For instance, Kimal PLC and Marizyme, Inc. announced a strategic partnership in February 2023 to support DuraGraft, the company's flagship product to prevent ischemia-reperfusion injury, a major contributing cause to vein graft disease.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Procedure Method, Surgical Procedure, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Coronary Artery Bypass Graft Market Report 2023 - 2034
Coronary Artery Bypass Graft Market Analysis & Forecast by Procedure Method 2023 - 2034 (Revenue USD Bn)
- Off-pump
- On-pump
- Minimally Invasive Direct
Coronary Artery Bypass Graft Market Analysis & Forecast by Surgical Procedure 2023 - 2034 (Revenue USD Bn)
- Single CABG Surgery
- Double CABG Surgery
- Triple CABG Surgery
- Quadruple CABG Surgery
Coronary Artery Bypass Graft Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Cardiology Centres
- Others
Coronary Artery Bypass Graft Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Coronary Artery Bypass Graft Market: Procedure Method Estimates & Trend Analysis
8. Coronary Artery Bypass Graft Market: Surgical Procedure Estimates & Trend Analysis
9. Coronary Artery Bypass Graft Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Coronary Artery Bypass Graft Market
12. Europe Coronary Artery Bypass Graft Market
13. Asia Pacific Coronary Artery Bypass Graft Market
14. Latin America Coronary Artery Bypass Graft Market
15. MEA Coronary Artery Bypass Graft Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Medtronic plc
- Abbott Laboratories
- Johnson & Johnson (Ethicon)
- Terumo Corporation
- Getinge AB
- LivaNova (Sorin Group)
- Edwards Lifesciences
- Boston Scientific Corporation
- Maquet (Getinge Group)
- Teleflex Incorporated.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 12.99 Billion |
| Forecasted Market Value ( USD | $ 35.14 Billion |
| Compound Annual Growth Rate | 9.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
